[Follow-up of Bladder Cancer : The Right Examinations at the Right Time]

Overview

Journal Urologe A

Specialty Urology

Date 2018 Apr 18

PMID 29663062

Authors

P Olbert

P J Goebell

A Hegele

Affiliations

Soon will be listed here.

Abstract

Schedules for the follow-up (FU) of bladder cancer patients are predominantly based on studies with low level of evidence and the resulting guidelines' recommendations that are often founded on expert consensus. FU of non-muscle invasive bladder cancer (NMIBC) includes cystoscopy and cytology as standard, and imaging modalities to a lower extent. FU of muscle-invasive bladder cancer (MIBC) depends primarily on the therapeutic modality chosen and on the stage of disease. In this scenario, FU is complemented by functional and quality of life related aspects. These apply even more for FU in palliative situations. Here, the individual focus is on examinations that might have a consequence in terms of survival and/or symptom relief.

References

Gamal El-Deen H, Elshazly H, Abo Zeina E . Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer. J Egypt Natl Canc Inst. 2010; 21(1):59-70. View

Mills R, Studer U . Metabolic consequences of continent urinary diversion. J Urol. 1999; 161(4):1057-66. View

Nieder A, Sved P, Gomez P, Kim S, Manoharan M, Soloway M . Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology. 2004; 64(5):950-4. DOI: 10.1016/j.urology.2004.06.012. View

Freeman J, Tarter T, Esrig D, Stein J, Elmajian D, Chen S . Urethral recurrence in patients with orthotopic ileal neobladders. J Urol. 1996; 156(5):1615-9. View

Canales B, Anderson J, Premoli J, Slaton J . Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol. 2006; 175(1):74-7. DOI: 10.1016/S0022-5347(05)00071-6. View

Cho K, Seo J, Park S, Lee Y, Choi Y, Cho N . The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. Urol Int. 2009; 82(3):306-11. DOI: 10.1159/000209363. View

Ghoneim M, Abol-Enein H . Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol. 2008; 5(9):501-8. DOI: 10.1038/ncpuro1202. View

Bochner B, Montie J, Lee C . Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am. 2003; 30(4):777-89. DOI: 10.1016/s0094-0143(03)00061-2. View

Gakis G, Black P, Bochner B, Boorjian S, Stenzl A, Thalmann G . Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. Eur Urol. 2016; 71(4):545-557. PMC: 5533286. DOI: 10.1016/j.eururo.2016.09.035. View

10.

Donat S . Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?. World J Urol. 2006; 24(5):557-64. DOI: 10.1007/s00345-006-0117-8. View

11.

Weiss C, Engehausen D, Krause F, Papadopoulos T, Dunst J, Sauer R . Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007; 68(4):1072-80. DOI: 10.1016/j.ijrobp.2007.01.054. View

12.

Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S . Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012; 188(6):2046-54. DOI: 10.1016/j.juro.2012.08.017. View

13.

Fernandez M, Parikh S, Grossman H, Katz R, Matin S, Dinney C . The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2011; 30(6):821-4. PMC: 3931457. DOI: 10.1016/j.urolonc.2010.08.006. View

14.

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A . The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011; 60(3):423-30. DOI: 10.1016/j.eururo.2011.05.033. View

15.

Shimko M, Tollefson M, Umbreit E, Farmer S, Blute M, Frank I . Long-term complications of conduit urinary diversion. J Urol. 2010; 185(2):562-7. DOI: 10.1016/j.juro.2010.09.096. View

16.

Weiss C, Wittlinger M, Engehausen D, Krause F, Ott O, Dunst J . Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys. 2007; 70(5):1502-6. DOI: 10.1016/j.ijrobp.2007.08.007. View

17.

Mohammed A, Hameed A, Shergill I, Barua J . The practice of the first check cystoscopy following radiotherapy for the treatment of muscle-invasive (T3N0M0) bladder cancer: a UK national survey. Int Urol Nephrol. 2010; 43(2):377-81. DOI: 10.1007/s11255-010-9789-5. View

18.

Aboziada M, Hamza H, Abdlrahem A . Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst. 2010; 21(2):167-74. View

19.

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

20.

Joung J, Han K, Kim T, Seo H, Chung J, Lee K . Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer. J Korean Med Sci. 2008; 23(4):598-603. PMC: 2526414. DOI: 10.3346/jkms.2008.23.4.598. View